Human Oncology & Pathogenesis Program

The Ingo Mellinghoff Lab

Share
Back to top

Research

Memorial Sloan Kettering medical oncologist Ingo Mellinghoff
Ingo K. Mellinghoff, MD, FACP

Our laboratory focuses on the study of molecular pathways that regulate brain tumor growth. Our long-term goal is to develop therapeutic paradigms that target specific properties of primary brain tumors, including genetic alterations in cancer signaling pathways, unique aspects of brain tumor metabolism, or interactions of brain tumor cells with their brain microenvironment. Our studies in experimental brain tumor models are closely linked to the evaluation of novel agents in early-phase clinical trials.

The Ingo Mellinghoff Lab

Featured News

MSK neuro-oncologist Ingo Mellinghoff
Experimental Drug for Low-Grade Glioma With IDH Gene Mutation Shows Promise

A new experimental drug could be an effective treatment for some people with low-grade glioma.
Treatment for Low-Grade Glioma Advances to Phase 3 Clinical Trial
Treatment for Low-Grade Glioma Advances to Phase 3 Clinical Trial

According to findings from a research team led by study first-author Ingo Mellinghoff, MD, Chair of MSK’s Department of Neurology: vorasidenib and ivosidenib reduced concentrations of 2-HG by more than 90%, were well-tolerated, and showed encouraging tumor responses amongst 49 patients enrolled in a multisite trial between April 2019 and April 2020. Vorasidenib showed greater brain penetration than ivosidenib. Based on the phase 1 trial results, vorasidenib was advanced to a phase 3 trial.
Ingo Mellinghoff, Chair of the Department of Neurology at Memorial Sloan Kettering
Brain Trust: 8 Questions with Ingo Mellinghoff

Ingo Mellinghoff is optimistic about the future of brain cancer treatments as the new Chair of MSK’s Department of Neurology.

View All Featured News

Publications

Mellinghoff IK, Lu M, Wen PY, Taylor JW, Maher EA, Arrillaga-Romany I, Peters KB, Ellingson BM, Rosenblum MK, Chun S, Le K, Tassinari A, Choe S, Toubouti Y, Schoenfeld S, Pandya SS, Hassan I, Steelman L, Clarke JL, Cloughesy TF. Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. Nat Med. 2023 Feb 23. doi: 10.1038/s41591-022-02141-2.

Glioblastoma and Other Primary Brain Malignancies in Adults: A Review. Schaff LR, Mellinghoff IK. Glioblastoma and Other Primary Brain Malignancies in Adults: A Review. JAMA. 2023 Feb 21;329(7):574-587. doi: 10.1001/jama.2023.0023.

Pourmaleki M, Jones CJ, Ariyan CE, Zeng Z, Pirun M, Navarrete DA, Li Y, Zhang M, Nandakumar S, Campos C, Nadeem S, Klimstra DS, Temple-Oberle CF, Brenn T, Lipson EJ, Schenk KM, Stein JE, Taube JM, White MG, Traweek R, Wargo JA, Kirkwood JM, Gasmi B, Goff SL, Corwin AD, McDonough E, Ginty F, Callahan MK, Schietinger A, Socci ND, Mellinghoff IK, Hollmann TJ. Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma. Cancer Immunol Res. 2022 Mar 1;10(3):303-313. doi: 10.1158/2326-6066.CIR-21-1083.

Tang CP, Clark O, Ferrarone JR, Campos C, Lalani AS, Chodera JD, Intlekofer AM, Elemento O, Mellinghoff IK. GCN2 kinase activation by ATP-competitive kinase inhibitors. Nat Chem Biol. 2022 Feb;18(2):207-215. doi: 10.1038/s41589-021-00947-8. Epub 2021 Dec 23.

Miller AM, Shah RH, Pentsova EI, Pourmaleki M, Briggs S, Distefano N, Zheng Y, Skakodub A, Mehta SA, Campos C, Hsieh WY, Selcuklu SD, Ling L, Meng F, Jing X, Samoila A, Bale TA, Tsui DWY, Grommes C, Viale A, Souweidane MM, Tabar V, Brennan CW, Reiner AS, Rosenblum M, Panageas KS, DeAngelis LM, Young RJ, Berger MF, Mellinghoff IK. Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Nature. 2019 Jan;565(7741):654-658. doi: 10.1038/s41586-019-0882-3. Epub 2019 Jan 23.

View All Publications

People

Memorial Sloan Kettering medical oncologist Ingo Mellinghoff

Ingo K. Mellinghoff, MD, FACP

  • Physician-scientist Ingo Mellinghoff studies signal transduction alterations in primary brain tumors.
  • MD, Technical University Munich (Germany)
646-888-2766
Office Phone
View physician profile
Physician profile

Members

Carl Campos
Carl Campos

Lab Manager

Christian Grommes, MD
Christian Grommes

Associate Attending

Maya Graham
Maya Graham

Instructor

Alexandra Miller
Alexandra Miller

Assistant Attending

Daniel Navarrete
Daniel Navarrete

Senior Research Assistant

Smrutiben Mehta
Smrutiben Mehta

Research Assistant

Charli Hertz
Charli Hertz

Research Technician

Brian Greenstein

Research Technician 

Marlene Tartaro

Research Technician

Maryam Pourmaleki
Maryam Pourmaleki

Graduate Student

Annalisa V. Ferrotta

Graduate Student

Arianna Izawa-Ishiguro
Arianna Izawa-Ishiguro

Pharmacology PhD Graduate Student

Lab Alumni
Owen Clark
Owen Clark

Senior Research Scientist

Alex Lee
Alex Lee

Research Technician

Veronica Nagle
Veronica Nagle

Graduate Student

Colin Tang
Colin Tang

Graduate Student

Sarah Tang
Sarah Tang
Lab Affiliations

Achievements

  • Neuro-Oncology Scientific Award, American Academy of Neurology (2023)
  • Member, Association of American Physicians (2020)
  • Member, American Society of Clinical Investigation (2013)
  • Advanced Clinical Research Award, American Society of Clinical Oncology (2009)
  • Clinical Scientist Development Award, Doris Duke Charitable Foundation (2008)
Read more
  • Translational Science Award, Sidney Kimmel Foundation (2008)
  • Distinguished Scientist, Sontag Foundation (2007)
  • Scholar, Forbeck Research Foundation (2005)
  • Young Investigator Award, American Society of Clinical Oncology (2003)

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Career Opportunities

Apply now

Get in Touch

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Ingo K. Mellinghoff discloses the following relationships and financial interests:

  • American Society of Clinical Oncology (ASCO)
    Provision of Services
  • Black Diamond Therapeutics, Inc.
    Provision of Services
  • Doris Duke Charitable Foundation
    Provision of Services
  • European Association of Neuro-Oncology (EANO)
    Provision of Services (uncompensated)
  • Roche
    Provision of Services
  • Servier
    Provision of Services
  • Voyager Therapeutics Inc.
    Provision of Services

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures

Related topics: